Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Meinertz, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Meinertz, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Mibefradil — a drug which may enhance the propensity for the development of abnormal QT prolongation

T. Meinertz*

Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany

* Correspondence: Thomas Meinertz, MD, Abteilung für Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, D-20246 Hamburg, Germany.

Abstract

Mibefradil is a moral calcium antagonist that is selective for the T-type voltage-operated calcium channel. It has been shown to be effective in hypertension and in stable angina. Shortly following its introduction, mibefradil was withdrawn from the market because of potentially harmful interactions with other drugs. Of special interest is the possible interaction of mibefradil with drugs which prolong the QT interval (e.g. amiodarone, quinidine, sotalol, erythromycin, desimipramine and thioridazine).

This short review summarizes the effects of mibefradil on cardiac repolarization and possible implications for drug interactions with QT prolonging agents.

Key Words: Mibefradil • cardiac repolarization • drug interactions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.